Sernova-Seraxis Close $11.2M Financing, Exceeding Target, to Fund Merger and Phase 1/2 Diabetes Trial
SEOVF sits 30% above its 52-week low of $0.06.
Summary
Sernova and Seraxis closed their convertible note financing at $11.2 million, above the $10 million target, with insiders from both companies participating. The proceeds fund the merger into BetaNova Biotherapeutics and advance SR-02, an allogeneic stem cell-derived islet cell therapy for type 1 diabetes, into a Phase 1/2 trial. Patient enrollment is set for Q4 2026, first dosing in Q1 2027, and initial data in H1 2027. The company also targets Nasdaq listing readiness in Q1 2027. This follows the September 8 merger announcement and provides concrete capital and timeline commitments. The financing's oversubscription and insider participation signal confidence, but the company remains pre-revenue with a market cap around $29 million, so execution risk is high. Watch for the merger completion and the start of patient enrollment in Q4.
At the time of this announcement, SEOVF was trading at $0.08 on OTC in the Life Sciences sector, with a market capitalization of approximately $29.3M. The 52-week trading range was $0.06 to $0.15. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.